Interpretation of the incremental impact of the RS-assay compared to CCP | |||||||
---|---|---|---|---|---|---|---|
Variable (range tested) | Negative cost and effect | Cost saving | ICER in the range | ICER in the range | ICER in the range | Dominated | |
0 to 20,000 $/QALY gained | 20,000 to 100,000 $/QALY gained | >100,000 $/QALY gained | |||||
Chemotherapy treated women in intermediate risk group by the RS-assay (0% to 100%) | 0% to 42% | 43% to 63% | 64% to 100% | Â | Â | Â | |
Change in absolute risk of relapseb in the RS-assay model (−10% to +10%) | > +1.8% | ≤ +1.8% |  |  |  |  | |
Change in utility of recurrencec (−10% to +10%) | Lower limit cost of recurrencec |  |  | ≤ +2.2% | +2.3% to +3.4% | +3.5% to +4% | ≥ +4% |
 | Baseline cost of recurrencec | > +3% | ≤ +3% |  |  |  |  |
 | Upper limit cost of recurrencec | > +3% | ≤ +3% |  |  |  |  |
Change in utility following adjuvant chemotherapy (−10% to +10%) | > +1% | ≤ +1% |  |  |  |  |